News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An investor comments on Scienture Holdings (SCNX.US), humorously pointing out the irony of the stock receiving a "buy" rating while simultaneously being unavailable for purchase. The comment expresses frustration over this perceived contradiction.
This article provides a quick overview of analyst ratings for Sight Sciences (SGHT.US), indicating a forecast share price between $8 and $12. It likely includes details on recent analyst actions and potential price targets for the company.
Sociedad Quimica y Minera de Chile SA (SQM) announced strong second-quarter earnings, reporting $660 million, which translates to $2.31 per share. These results surpassed Wall Street expectations, with analysts having projected earnings of $2.03 per share. The chemicals company also posted revenues of $2.47 …
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its …
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of company stock for $138.36 per share, totaling $415,080, on August 17, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite the sale, Dickinson still beneficially owns 165,646 shares, and the stock …
Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 284,707 shares of the company's stock for approximately $10.3 million on August 17th, 2026, reducing his position by 1.51%. This follows two other recent sales by Sukhatme. Despite these insider sales, analysts maintain a "Moderate …
Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, exercised stock options for 664,826 common shares at $3.85 per share across August 14, 17, and 18, 2026. These shares were then sold in open-market transactions with weighted average prices ranging from $36.23 to $37.18. The …
Roivant Sciences insider Mayukh Sukhatme sold 243,177 shares for approximately $8.81 million, retaining 18.63 million shares. This sale is part of three recent transactions totaling around $24.16 million. Despite a quarterly loss, Roivant Sciences beat analyst estimates and its shares rose 3.1% to near …
Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 136,942 shares of the company's stock for approximately $5.03 million. Despite this recent sale, Sukhatme still directly owns 18.63 million shares and had prior sales totaling over $19.1 million in August. Roivant Sciences' stock saw …
Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares …
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of the company's stock for $415,080 under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 1.78%. This sale comes as Gilead's stock rose 3.3% to $143.44, following better-than-expected quarterly results and a declared dividend …
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth …
Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 28,000 shares of company stock for approximately $3.85 million on August 17, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred alongside the exercise of non-qualified stock …
Thermo Fisher Scientific (TMO) has completed large-scale Olink Explore HT proteomic analysis on Parkinson's samples from The Michael J. Fox Foundation, making the data accessible for research. This initiative reinforces Thermo Fisher's role in precision medicine and its focus on innovation and recurring revenue. …
5AM-affiliated funds and individuals have updated their beneficial ownership in Skye Bioscience (SKYE) and detailed a strategic merger with Redx Pharma Limited. Skye will acquire Redx shares through a UK Scheme of Arrangement, with Redx pre-transaction equity holders expected to own 46.17% of the …
Ciena's stock dropped by almost 9% after TD Cowen analyst Joshua Buchalter lowered his fair value assessment for the company from $675 to $575 per share. Despite this reduction, Buchalter maintained a "buy" recommendation, citing recent price weakness and overall bullish prospects for semiconductor …
PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted …
Gilead Sciences insider Johanna Mercier sold 28,000 shares of GILD stock for $3.85 million at an average price of $137.64, reducing her holdings by 19.15%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Gilead's stock traded up …
Ciena CFO Marc Graff sold 4,995 shares of CIEN stock on August 14th for over $2.15 million, reducing his position by 4.44%. The stock experienced a 9.0% decline on Tuesday, trading at $405.03. Despite the sale and stock drop, Ciena reported strong quarterly earnings, …
Marc D. Graff, Senior Vice President and Chief Financial Officer at CIENA CORP, sold 4,995 shares of the company's common stock for over $2.15 million on August 14, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred after CIENA's stock surged …
Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to …
Gilead Sciences, Inc. (NASDAQ: GILD) Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on August 17, 2026, at a price of $138.36 per share. This transaction was carried out under a pre-adopted Rule 10b5-1 trading plan. After the sale, Mr. …
H.C. Wainwright has increased its price target for Alto Neuroscience (NYSE:ANRO) to $55 from $50, maintaining a Buy rating. This adjustment follows Alto's announcement of its Q2 2026 results and the naming of its ALTO-207 development plan as the PACE program, which includes three …
Gilead Sciences Inc (GILD) shares increased by 3.2% to $143.44, but GuruFocus's GF Value indicates the stock is 34.9% overvalued, with an estimated intrinsic value of $106.32. The company's GF Score is 74/100, highlighting strong profitability but weak momentum and insider selling of $77.5 …
David M. Rothenstein, SVP and Chief Strategy Officer of Ciena (NYSE: CIEN), sold 2,500 shares of common stock on August 14, 2026, at $438.10 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on October 10, 2025. Following the sale, …
Search by ticker symbol or company name and select a result to open its chart.